Antiplatelet agents

The landmark Dual Antiplatelet Therapy ( DAPT ) trial revealed an impressive reduction of stent thrombosis and myocardial infarction after...


Lacunar stroke accounts for approximately 25% of ischemic stroke, but optimal antiplatelet regimen to prevent stroke recurrence remains unclear. A...


A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial...


The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) issued...


ESC Guidelines recommended for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention ( PCI...


American Heart Association ( AHA ) and American College of Cardiology ( ACC ) have updated the guideline for the...


Venous and arterial thromboses have been regarded for many years as two different diseases requiring anticoagulant or antiplatelet treatment, respectively....


In February 2014, the American Heart Association [ AHA ] /American Stroke Association [ ASA ] released their first guideline...


Morphine is recommended in patients with ST-segment-elevation myocardial infarction, including those undergoing primary percutaneous coronary intervention ( PCI ). Suboptimal...


MHRA ( Medicines and Healthcare Products Regulatory Agency ) previously advised that the contraindications for Dabigatran ( Pradaxa ) had...


Results of a phase III clinical trial has shown that a simple drug regimen of two anti-clotting drugs, Clopidogrel (...


The presentation of the PLATO ( A Study of Platelet Inhibition and Patient Outcomes ), showed that Ticagrelor ( Brilinta...


Heightened platelet activity plays a critical role in thrombus formation, which is central to acute coronary syndromes ( ACS ),...


A large international study has demonstrated that patients with atherothrombosis ( coronary artery disease, cerebrovascular disease, peripheral arterial disease )...


A large international study has demonstrated that patients with atherothrombosis ( coronary artery disease, cerebrovascular disease, peripheral arterial disease )...


Patients with myocardial infarction who stopped taking antiplatelet drugs within 30 days of receiving a drug-coated stent had nine times...


Data from the PROactive Study, presented at the 41st meeting of the European Association for the Study of Diabetes (...


Results from three early-phase, cross-over studies demonstrated that all subjects responded to Prasugrel ( Effient ), an investigational antiplatelet agent,...